China, AstraZeneca

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...